Table 3 Medications for HBV and HCV patients in the study period (grouped by use of angiotensin converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs] used in the initial 6Â months after index date)
| Â | Â | HBV patients | Â | Â | HCV patients | Â |
|---|---|---|---|---|---|---|
Variables | All | Initial exposure | Initial non-exposure | All | Initial exposure | Initial non-exposure |
n | 7724 | 3575 | 4149 | 7873 | 3349 | 4524 |
ACEI/ARB | Â | Â | Â | Â | Â | Â |
 DDD | 1.0 (0.7–1.3) | 1.0 (0.7–1.3) | 0.9 (0.5–1.1) | 1.0 (0.7–1.3) | 1.0 (0.8–1.3) | 0.9 (0.5–1.1) |
 Duration (months) | 36.4 (12.5–50.0) | 41.8 (22.2–53.6) | 18.3 (3.0–35.9) | 38.9 (18.4–53.1) | 46.4 (36.1–57.9) | 22.7 (6.8–38.6) |
Aspirin | Â | Â | Â | Â | Â | Â |
 DDD | 1.6 (0.9–2.0) | 1.7 (1.0–2.0) | 1.5 (0.9–1.9) | 1.6 (0.9–1.9) | 1.7 (1.0–2.0) | 1.5 (0.9–1.9) |
 Duration (months) | 22.0 (3.3–44.5) | 25.1 (4.9–45.5) | 18.3 (1.5–42.4) | 24.9 (4.9–46.9) | 30.6 (7.1–48.6) | 21.0 (3.1–45.3) |
Metformin | Â | Â | Â | Â | Â | Â |
 DDD | 0.5 (0.3–0.7) | 0.5 (0.3–0.7) | 0.5 (0.3–0.6) | 0.5 (0.3–0.6) | 0.5 (0.3–0.7) | 0.5 (0.3–0.6) |
 Duration (months) | 26.7 (7.3–44.6) | 29.5 (8.9–45.3) | 23.6 (5.8–43.6) | 35.5 (13.7–50.3) | 37.3 (17.6–49.7) | 31.4 (10.0–50.8) |
Statin | Â | Â | Â | Â | Â | Â |
 DDD | 0.5 (0.3–0.8) | 0.5 (0.3–0.8) | 0.5 (0.3–0.8) | 0.5 (0.3–0.7) | 0.5 (0.3–0.7) | 0.5 (0.3–0.7) |
 Duration (months) | 23.3 (6.3–43.9) | 25.7 (7.4–44.6) | 20.7 (5.5–42.8) | 20.0 (5.7–38.5) | 22.5 (7.2–39.1) | 17.4 (4.9–37.3) |